How Parasites Evade the Immune System

Table of Contents

1. What the Presentation Said
2. The Problem a Parasite Has to Solve
3. Life Cycles and Changing Form
4. Changing Coats: Malaria and Trypanosomes
5. Disguise and Armour: Blood Flukes
6. How Worms Calm the Immune System
7. The Hygiene Hypothesis
8. Worms as Treatment: The Clinical Trials
9. Biofilms, Autoimmune Disease and the Other Claims
10. How the Claim Compares With the Research
11. What Is Not Known
12. Connections
13. Key Research Papers
14. Featured Videos

What the Presentation Said

The presentation was a 2026 webinar on cancer and parasites given by the medical director of an integrative cancer clinic. In the part covered by this page, the speaker made these points:

• Parasites secrete enzymes that dissolve their own waste and help them escape detection, and over a very long history they have developed whole mechanisms for getting past the immune system.
• Parasites suppress immune signalling, creating an environment in which infection and disease can flourish, and in this way speed up ageing and tissue breakdown.
• The speaker linked parasites to chronic fatigue, to “any autoimmune disease” including lupus, to allergies, digestive problems, skin problems and inflammation of the nervous system. Elsewhere in the talk the speaker said parasitic infection is often misdiagnosed as an autoimmune or chronic disorder such as irritable bowel syndrome.
• Showing a simplified life-cycle diagram, the speaker said parasites have complex life cycles from egg to adult, and, citing a book the speaker did not name in the transcript, that parasites can change form (the speaker used the word “polymorphism”) and so evade both the immune system and treatments.
• The speaker said a biofilm is an important target, and that the parasite manipulates the host’s immune resources in order to feed itself.
• Later the speaker said the immune system cannot detect these parasites and other microbes, and tied this immune dysregulation to cancer development.

The speaker did not cite a scientific study for these points in this part of the talk, and did not name any particular parasite species when describing immune evasion. This page therefore tests the general claim against the parasites researchers have studied most closely: malaria parasites, African trypanosomes, blood flukes (schistosomes), intestinal worms and Toxoplasma.

The Problem a Parasite Has to Solve

The immune system has two broad arms. The innate arm reacts within minutes to hours, using white cells that swallow invaders and a set of blood proteins called complement that punch holes in foreign surfaces. The adaptive arm takes days to weeks to get going, but it learns: B cells make antibodies that lock onto a specific molecule (an antigen) on the invader’s surface, and T cells coordinate the attack. Once the adaptive arm has learned an antigen, it remembers it.

A bacterium or virus usually wins or loses the race within days or weeks. Most parasites play a much longer game. A review of human worm infections by Allen and Maizels (1996) notes that these large organisms can survive for years in the host and have evolved elaborate immune-evasion strategies, including inducing tolerance to their own antigens. To do that, a parasite has to solve one or more of these problems:

• Not being recognised — hiding inside cells, or wearing a surface that the immune system either cannot see or has not learned yet.
• Surviving recognition — having an outer layer that resists attack, or switching the surface faster than antibodies can follow.
• Turning the response down — releasing molecules that calm the host’s immune cells.

Published research shows parasites using all three approaches. Different parasites rely on different ones, as the following sections describe.

Life Cycles and Changing Form

The presentation’s point that parasites have complex life cycles and change form is standard parasitology. Most parasites pass through several distinct stages, often in more than one host species, and each stage carries different surface molecules and lives in a different place in the body.

Blood flukes: two hosts, two immune systems

Schistosomes, the worms that cause schistosomiasis, spend part of their life in freshwater snails and part in people. The review by Hambrook and Hanington (2020) describes how they face the snail’s innate defences in one phase and the full human innate and adaptive immune system in the other, and how they cope with both. The larvae that burrow through human skin change into a new form as they enter, and the adult worms then live in blood vessels for years.

Toxoplasma: going quiet inside cysts

Toxoplasma gondii, a single-celled parasite carried by cats and found in undercooked meat, has a fast-dividing stage (the tachyzoite) and a slow, dormant stage (the bradyzoite) that sits inside tissue cysts, mainly in brain and muscle. The review by Sullivan and Jeffers (2012) describes this conversion as central to how the parasite persists: the cysts let it stay in the body long term, and they can reactivate and cause disease if the host’s immunity later weakens, for example in people with advanced human immunodeficiency virus (HIV) or on strong immune-suppressing medicines.

Malaria: a drug target that keeps moving

The malaria parasite Plasmodium falciparum passes through liver, blood and mosquito stages, and inside red blood cells it moves through ring, trophozoite and schizont forms in roughly two days. A laboratory study by Murithi and colleagues (2020), in cell culture, profiled how blood-stage parasites at each step respond to standard and experimental antimalarial drugs and found clear stage-specific patterns: some drugs act mainly on one stage. This is one documented sense in which a parasite’s changing form affects how well treatment reaches it — and it is why drug combinations are used for malaria.

Changing Coats: Malaria and Trypanosomes

The clearest proof that parasites evade the immune system comes from antigenic variation: the parasite keeps a library of surface-protein genes and switches which one it uses, so that by the time the host has made antibodies against one coat, part of the population has moved on to another.

Malaria parasites and PfEMP1

Plasmodium falciparum places a protein called PfEMP1 on the surface of the red blood cells it infects. The review by Scherf and colleagues (2008) explains that PfEMP1 is encoded by a family of about 60 var genes, that each parasite switches on only one at a time while keeping the rest silent, and that the switching is controlled by epigenetic marks (chemical tags on DNA-packaging proteins, rather than changes in the DNA sequence). PfEMP1 also makes infected red cells stick to the walls of small blood vessels, and this sticking contributes to severe disease.

The human side of this is visible in antibody studies. In a study of 36 Kenyan children with symptomatic malaria, Tuju and colleagues (2019) measured antibodies against 36 different versions of part of PfEMP1. The children’s antibody patterns fell into two types: one was found in 19 of the 20 children who developed severe malaria, the other in all 16 children with mild disease. The children with severe malaria had narrower, shorter-lived antibody responses. The authors present this as a route toward a vaccine that targets the protective version of the response.

African trypanosomes and the VSG coat

Trypanosoma brucei, the single-celled parasite that causes sleeping sickness, lives free in the blood and is covered in a dense coat of a single protein, the variant surface glycoprotein (VSG). By switching which VSG gene is expressed, the parasite repeatedly escapes the antibodies the host has made against the previous coat, which produces the waves of parasites in the blood seen in this infection.

The VSG coat is not the only trick. In laboratory work, Mikkelsen and colleagues (2024) found that another trypanosome surface protein, ISG75, binds the tail end of human antibodies (the Fc region of immunoglobulin G (IgG)). In their experiments this blocked the classical complement pathway and blocked white cells from engulfing antibody-coated targets — in effect, the parasite disarms antibodies that do manage to stick to it. This is a test-tube finding about how the protein behaves, not a measurement in patients.

Disguise and Armour: Blood Flukes

Adult schistosomes are centimetre-long worms that live in the veins around the gut or bladder, bathed in blood full of antibodies and white cells, for years at a time. The review by Hambrook and Hanington (2020) groups their survival methods into four main families:

• Molecular mimicry — displaying molecules that resemble the host’s own, so the worm looks less foreign.
• An immune-resistant outer layer — the worm’s surface, the tegument, is a living double membrane that resists immune attack and can be renewed.
• Potent proteases — enzymes the larvae and worms secrete, which among other things help them break through skin and can cleave host defence molecules.
• Targeted release of immune-modulating factors that change how host immune cells behave.

The presentation said parasites secrete enzymes that dissolve their own waste to escape detection. The proteases described in schistosome research are real, but the research describes them as tools for invasion, feeding and disarming host defences. The searches for this page found no study describing parasite enzymes that dissolve the parasite’s own waste as an immune-evasion mechanism.

How Worms Calm the Immune System

Parasitic worms (helminths) provoke a distinctive kind of immune response called a type 2 or Th2 response — the same branch involved in allergies. It features high levels of immunoglobulin E (IgE) antibodies, raised eosinophils (a white cell that shows up in blood tests during worm infections) and activated mast cells. Allen and Maizels (1996) point out a puzzle: despite high immunoglobulin E and other features of this allergic-type activation, allergic reactions are rarely seen in infected people.

The explanation that research has built since then is immunomodulation — worms actively turning the host’s response down. The review by Wiedemann and Voehringer (2020) describes a growing list of helminth-derived molecules with strong immune-calming activity, studied mostly in schistosomes and in mouse models of hookworm infection. Effects described in the research literature include:

• More regulatory T cells, the immune cells that act as brakes on other immune cells.
• More of the calming signalling molecule interleukin-10. Yazdanbakhsh and colleagues (2002) note that raised interleukin-10 during long-term worm infection has been shown to be inversely correlated with allergy.
• Tolerance to the parasite’s own antigens, so that the host stops attacking them.

Larvae that never finish their life cycle in people use similar tools. The review by Abou-El-Naga and Mogahed (2023) describes how larvae of the dog roundworm Toxocara canis survive for long periods in human and animal tissues by releasing a mixture of excretory-secretory molecules that push the immune response toward a type 2 and regulatory pattern.

So the presentation’s statement that parasites suppress immune signalling describes something real. The research frames it as a targeted dampening that protects the worm — and, in some studies, appears to protect the host from excessive inflammation too. That second point is the basis of the hygiene hypothesis.

The Hygiene Hypothesis

As Bloomfield and colleagues (2006) summarise, the hygiene hypothesis as originally formulated proposed that fewer infections in early childhood, of the kind passed on through close contact with older brothers and sisters, might explain the rapid rise in allergic disease in wealthy countries.

The idea has since changed shape. The same review concludes that the rise in allergies does not line up with the fall in infection with disease-causing organisms, and cannot be explained by changes in household cleanliness. A consensus has moved toward the view that wider lifestyle changes reduced exposure to certain microbes and to helminths that help train the immune system’s regulatory side. The authors conclude that a link to hygiene practice is not proven, state that their review lends strong support to efforts to improve hygiene, and propose renaming the idea the “microbial exposure” or “microbial deprivation” hypothesis.

Yazdanbakhsh and colleagues (2002) explain why the first, simple version (too few infections push the immune system toward allergy) did not fit the facts: autoimmune diseases of the opposite immune type were rising at the same time, and worm infections, which drive the allergic-type response, were not associated with more allergy. Their proposed unifying explanation is that persistent infections such as worms build a robust anti-inflammatory regulatory network. Whether worms shape immunity mainly in early life, or can still dampen established inflammatory disease in adults, is an open research question — and the second possibility is what the therapy trials set out to test.

Wammes and colleagues (2014) describe the other side of the coin: deworming is rightly advocated in endemic areas to prevent the harm worms cause, but because worms modulate inflammation and metabolism, the authors raise the question of whether mass deworming could unmask inflammatory and metabolic conditions, and call for studies in endemic countries.

Worms as Treatment: The Clinical Trials

If worms calm the immune system, could a controlled worm infection calm a disease driven by an overactive one? Researchers tested this by giving patients eggs of the pig whipworm, Trichuris suis (known in trials as TSO, Trichuris suis ova), a worm adapted to pigs rather than people, or a small dose of human hookworm larvae. Wammes and colleagues (2014) list registered trials of whipworm eggs in allergies, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, psoriasis and autism, and of hookworm larvae in allergic rhinitis, asthma, coeliac disease and multiple sclerosis.

The early, encouraging results

• Crohn’s disease, open-label. Summers and colleagues (2005, Gut) gave 29 people with active Crohn’s disease 2,500 live pig whipworm eggs every three weeks for 24 weeks. At week 24, 23 (79.3%) had responded and 21 (72.4%) were in remission by the disease-activity score, with no adverse events reported. There was no placebo group, so everyone knew they were being treated.
• Ulcerative colitis, randomised. In a placebo-controlled trial in 54 people, the same group (Summers and colleagues, 2005, Gastroenterology) gave 2,500 eggs every two weeks for 12 weeks. Improvement on the disease-activity index occurred in 13 of 30 (43.3%) on eggs versus 4 of 24 (16.7%) on placebo (P = .04). The proportion reaching a near-normal score (remission) did not differ significantly.

The larger trials

• Cochrane review, 2014. Garg and colleagues found only two randomised trials (90 participants) and concluded there was insufficient evidence for any firm conclusion about the efficacy and safety of worm therapy in inflammatory bowel disease, rating the evidence as low quality because the numbers were so small.
• Crohn’s disease, randomised, 252 adults. In the multicentre trial reported by Schölmerich and colleagues (2017), adults with mild-to-moderate active Crohn’s disease received 250, 2,500 or 7,500 eggs or placebo every two weeks for 12 weeks. Remission at week 12 occurred in 38.5%, 35.2% and 47.2% on the three egg doses, and in 42.9% on placebo. The eggs triggered a dose-dependent immune response and caused no serious adverse reactions, but no dose showed a clinically relevant benefit over placebo.
• Ulcerative colitis, randomised, 119 adults. In the trial reported by Prosberg and colleagues (2024), 7,500 eggs every two weeks for 24 weeks gave clinical remission in 30% versus 34% on placebo — no difference. A temporary improvement in symptoms at week 12 was seen in a subgroup who did not need steroids during the trial.
• Multiple sclerosis, hookworm, 71 adults. Tanasescu and colleagues (2020) gave 25 human hookworm larvae (Necator americanus) through the skin, or placebo, to people with relapsing multiple sclerosis who were not on disease-modifying treatment. Over nine months, the main measure — new or enlarging lesions on magnetic resonance imaging (MRI) scans — was not significantly different between groups. Regulatory T cells in the blood rose in the hookworm group (4.4% versus 3.9%), there were 5 relapses on hookworm versus 11 on placebo, and skin discomfort where the larvae were applied was much more common with hookworm (82% versus 28%). The authors attributed the missed primary outcome partly to low disease activity in the trial population.

Taken together, the trials confirm that worm exposure measurably changes human immune responses, and that it was generally well tolerated in these short trials. The hoped-for clinical benefit in Crohn’s disease and ulcerative colitis was not confirmed in the larger placebo-controlled trials, and the multiple sclerosis trial missed its main endpoint. Researchers have since shifted much of their attention to isolating individual worm-derived molecules, an approach reviewed by Wiedemann and Voehringer (2020).

Biofilms, Autoimmune Disease and the Other Claims

Biofilms

A biofilm is a slimy community of microbes stuck to a surface and wrapped in a self-made matrix — dental plaque is the familiar example. Biofilms are well documented for bacteria and fungi, and they do make infections harder to treat. The PubMed searches done for this page, including a search on parasites and biofilms, returned studies of bacterial and fungal biofilms in the mouth and vagina, not of parasitic worms or protozoa protecting themselves with biofilms in people. No study examined for this page showed that a parasite biofilm is a target for treatment. The presentation did not say which parasite or biofilm it meant.

Autoimmune disease, allergy and chronic illness

The presentation linked parasites to “any autoimmune disease”, to lupus and to allergies. The bulk of the research reviewed on this page points the other way for worms: epidemiological and mechanistic studies associate helminth infection with less allergy and less autoimmune inflammation, which is why worms were tested as a treatment. That does not make worms harmless — Allen and Maizels (1996) note that the type 2 response itself may be responsible for immune-mediated damage, and some parasites do cause rashes, itching, asthma-like lung symptoms and organ damage. And a parasitic infection can be mistaken for another disease; that is covered on the sibling page Parasites Misdiagnosed as Other Diseases.

No study examined for this page showed parasites causing lupus or autoimmune disease in general, or causing chronic fatigue or accelerated ageing.

“The immune system can’t detect these parasites”

The research describes evasion, not invisibility. Worm infections produce strong, measurable immune signatures — raised eosinophils and immunoglobulin E, and antibodies that blood tests can detect — and malaria immunity built up over years of exposure protects many adults in endemic areas from severe disease, as the PfEMP1 antibody work shows. Parasites survive by staying a step ahead of, hiding from, or turning down a response the immune system clearly mounts.

How the Claim Compares With the Research

Supported by the research

• Parasites have complex life cycles and change form. Standard parasitology; documented in detail for schistosomes, Toxoplasma and malaria parasites.
• Parasites have evolved mechanisms that evade the immune system. Strongly documented: antigen switching in malaria parasites and trypanosomes, mimicry and a resistant outer layer in schistosomes, antibody and complement disarming, dormant tissue cysts in Toxoplasma.
• Parasites suppress immune signalling. Supported for helminths in particular, which raise regulatory T cells and interleukin-10 and induce tolerance — confirmed in people by the rise in regulatory T cells in the hookworm trial.

Supported only in part

• Changing form helps parasites escape treatment. Laboratory work shows malaria drugs act differently on different blood stages, and dormant Toxoplasma cysts can reactivate later. But the research does not show this as a general reason why antiparasitic treatment fails.
• Parasites secrete enzymes to escape detection. Schistosomes do secrete potent proteases, and these play a role in invasion and in dealing with host defences. No research was found for the specific idea of enzymes that dissolve the parasite’s own waste.
• Parasites manipulate the host’s immune resources. True of immunomodulation in general; no research was found linking it to the parasite “feeding itself” on immune resources.

Contradicted by the research

• The immune system cannot detect parasites. Hosts mount clear, measurable responses; parasites survive by evading and dampening them, not by being invisible.
• Parasites contribute to any autoimmune disease and to allergies. For worms, the epidemiology and the hygiene-hypothesis research mostly report the opposite association — less allergy and autoimmunity in heavily infected populations — although worm infections cause their own immune-driven damage.

No research found

• A parasite biofilm as a treatment target in people.
• Parasites as a cause of lupus, chronic fatigue or accelerated ageing.
• The unnamed book on parasite “polymorphism” could not be identified from the transcript.

What Is Not Known

• Why the worm-therapy trials failed. It is not known whether the dose, the timing (adult disease rather than early-life exposure), the choice of a pig parasite rather than a human one, or the disease itself explains the gap between animal results, early human results and the larger placebo-controlled trials.
• Whether individual worm molecules will work better. Many immune-calming molecules have been isolated from worms, but few have reached human testing.
• What mass deworming does to allergy and autoimmunity. Wammes and colleagues (2014) list this as an open question that needs studies in endemic countries.
• How malaria immunity is built. Whether protection comes from exposure to many PfEMP1 types one by one, from cross-reactive antibodies, or from something else is still being worked out, and it shapes the search for an anti-disease malaria vaccine.
• How much worm-induced immune dampening matters for other infections or for cancer. This is explored on the sibling pages linked below; human evidence is limited.

Decisions about parasitic infection, autoimmune disease and their treatment belong with a clinician.

Connections

• Cancer and Parasites
• How Parasites Can Drive Cancer: The Mechanisms
• Malaria and Burkitt Lymphoma
• Parasites Misdiagnosed as Other Diseases
• The Gut Microbiome and Parasites
• Immunology
• Parasites
• Malaria
• Trypanosoma
• Schistosoma
• Whipworm
• Hookworm
• Toxoplasma
• Toxocara
• Crohn’s Disease
• Ulcerative Colitis
• Multiple Sclerosis

Key Research Papers

1. Allen JE, Maizels RM. Immunology of human helminth infection. Int Arch Allergy Immunol. 1996;109(1):3-10. PubMed PMID: 8527948
2. Hambrook JR, Hanington PC. Immune Evasion Strategies of Schistosomes. Front Immunol. 2020;11:624178. PubMed PMID: 33613562
3. Wiedemann M, Voehringer D. Immunomodulation and Immune Escape Strategies of Gastrointestinal Helminths and Schistosomes. Front Immunol. 2020;11:572865. PubMed PMID: 33042153
4. Scherf A, Lopez-Rubio JJ, Riviere L. Antigenic variation in Plasmodium falciparum. Annu Rev Microbiol. 2008;62:445-70. PubMed PMID: 18785843
5. Tuju J, Mackinnon MJ, Abdi AI, et al. Antigenic cartography of immune responses to Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1). PLoS Pathog. 2019;15(7):e1007870. PubMed PMID: 31260501
6. Murithi JM, Owen ES, Istvan ES, et al. Combining Stage Specificity and Metabolomic Profiling to Advance Antimalarial Drug Discovery. Cell Chem Biol. 2020;27(2):158-171.e3. PubMed PMID: 31813848
7. Mikkelsen JH, Stødkilde K, Jensen MP, et al. Trypanosoma brucei Invariant Surface Glycoprotein 75 Is an Immunoglobulin Fc Receptor Inhibiting Complement Activation and Antibody-Mediated Cellular Phagocytosis. J Immunol. 2024;212(8):1334-1344. PubMed PMID: 38391367
8. Sullivan WJ Jr, Jeffers V. Mechanisms of Toxoplasma gondii persistence and latency. FEMS Microbiol Rev. 2012;36(3):717-33. PubMed PMID: 22091606
9. Abou-El-Naga IF, Mogahed NMFH. Potential roles of Toxocara canis larval excretory secretory molecules in immunomodulation and immune evasion. Acta Trop. 2023;238:106784. PubMed PMID: 36502886
10. Yazdanbakhsh M, Kremsner PG, van Ree R. Allergy, parasites, and the hygiene hypothesis. Science. 2002;296(5567):490-4. PubMed PMID: 11964470
11. Bloomfield SF, Stanwell-Smith R, Crevel RW, et al. Too clean, or not too clean: the hygiene hypothesis and home hygiene. Clin Exp Allergy. 2006;36(4):402-25. PubMed PMID: 16630145
12. Wammes LJ, Mpairwe H, Elliott AM, et al. Helminth therapy or elimination: epidemiological, immunological, and clinical considerations. Lancet Infect Dis. 2014;14(11):1150-1162. PubMed PMID: 24981042
13. Summers RW, Elliott DE, Urban JF Jr, et al. Trichuris suis therapy in Crohn's disease. Gut. 2005;54(1):87-90. PubMed PMID: 15591509
14. Summers RW, Elliott DE, Urban JF Jr, et al. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology. 2005;128(4):825-32. PubMed PMID: 15825065
15. Garg SK, Croft AM, Bager P. Helminth therapy (worms) for induction of remission in inflammatory bowel disease. Cochrane Database Syst Rev. 2014;(1):CD009400. PubMed PMID: 24442917
16. Schölmerich J, Fellermann K, Seibold FW, et al. A Randomised, Double-blind, Placebo-controlled Trial of Trichuris suis ova in Active Crohn's Disease. J Crohns Colitis. 2017;11(4):390-399. PubMed PMID: 27707789
17. Prosberg MV, Halkjær SI, Lo B, et al. Probiotic Treatment of Ulcerative Colitis with Trichuris Suis Ova: A Randomised, Double-blinded, Placebo-controlled Clinical Trial [the PROCTO Trial]. J Crohns Colitis. 2024;18(11):1879-1893. PubMed PMID: 38899778
18. Tanasescu R, Tench CR, Constantinescu CS, et al. Hookworm Treatment for Relapsing Multiple Sclerosis: A Randomized Double-Blinded Placebo-Controlled Trial. JAMA Neurol. 2020;77(9):1089-1098. PubMed PMID: 32539079

PubMed Topic Searches

1. Helminth immune evasion and immunomodulation
2. Antigenic variation in malaria parasites and trypanosomes
3. The hygiene hypothesis, helminths and allergy
4. Helminth therapy randomised trials

Featured Videos